Anavex Life Sciences
AVXL
181 hedge funds and large institutions have $269M invested in Anavex Life Sciences in 2025 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 45 reducing their positions, and 25 closing their positions.
65% more call options, than puts
Call options by funds: $14.7M | Put options by funds: $8.92M
52% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 25
29% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 45
8% more funds holding
Funds holding: 168 → 181 (+13)
2.04% more ownership
Funds ownership: 34.84% → 36.88% (+2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less capital invested
Capital invested by funds: $316M → $269M (-$47M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$7.58M |
| 2 |
LPL Financial
San Diego,
California
|
+$4.27M |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$2.59M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.09M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sculptor Capital
New York
|
-$3.97M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.28M |
| 3 |
EP
Essential Planning
Portsmouth,
New Hampshire
|
-$3.25M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.27M |
| 5 |
Renaissance Technologies
New York
|
-$1.88M |
AVXL Hedge Fund Activity: Q1 2025 in Review
181 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q1 2025, worth a combined $269M — down 15% from $316M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new AVXL positions and 25 closed out — a net gain of 13 holders — while 58 added to existing stakes and 45 trimmed.
The largest buyer was State Street, adding an estimated $7.58M. The largest seller was Sculptor Capital, exiting entirely with an estimated $3.97M sold.
- 181 institutional investors held Anavex Life Sciences (AVXL) as of Q1 2025, up from 168 in Q4 2024.
- Funds reported $269M of Anavex Life Sciences stock for Q1 2025, down 15% quarter-over-quarter.
- 38 funds opened new Anavex Life Sciences positions in Q1 2025 and 25 closed out, a net change of +13 holders.
- The largest Anavex Life Sciences buyer in Q1 2025 was State Street, an estimated $7.58M added.
- The largest Anavex Life Sciences seller in Q1 2025 was Sculptor Capital, an estimated $3.97M sold.
Based on aggregated 13F filings for Q1 2025.